Preliminary results are available from a phase 2 trial of first-line dacomitinib in 74 patients with adenocarcinoma who were either nonsmokers/former light smokers or had documented EGFR mutations; median PFS was 9.30 months in all patients, but had not been reached in the 27-patient subset with confirmed EGFR mutations (all of whom had experienced tumor shrinkage) 40. This evidence concerns the gene EGFR and neoplasm.